Jérémie Meyer, Author at BaseLaunch

All Features

KPMG: COVID-19 feature- Build resilience

From our partner, KPMG: Proving an online knowledge base for the COVID-19 times. KPMG has put together an online resource page for these challenging and…

Jérémie Meyer08.05.2020

All Portfolio news

Anaveon raises CHF 35 million

Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the…

Jérémie Meyer05.03.2020

All Portfolio news

Polyneuron raises CHF 22.5 million in Series A financing

Polyneuron Pharmaceuticals, one of our portfolio companies has successfully raised 22.5 million francs in a round of financing. The Basel-based company will use the proceeds…

Jérémie Meyer04.03.2020

All Portfolio news

Alentis raises 12.5 million Swiss francs

The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by…

Jérémie Meyer03.03.2020

All Portfolio news

T3 Pharma raises over $12 million

T3 Pharma, a spin-off of the University of Basel and one of our portfolio, has raised over $12 million from Boehringer Ingelheim Venture Fund and…

Jérémie Meyer02.03.2020

All Portfolio news

Versameb raises 6.4 million Swiss francs

Basel-based biopharmaceutical Versameb has raised 6.4 million Swiss francs in a Seed C financing round and will put the funds towards expanding its technology platform.…

Jérémie Meyer01.03.2020

Features

CHF 15M in Series A Financing, raised by ImmunOs

ImmunOs Therapeutics AG is a Swiss biotechnology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer. They have recently…

Jérémie Meyer17.12.2019

Features

KPMG: Reshaping the future of pharma

From our partner, KPGM: The rules of engagement in the global pharmaceutical industry are changing rapidly with disruption in this industry already well underway. Two…

Jérémie Meyer06.12.2019

Company interviews Interviews

“The first steps are slow and then suddenly things start rolling”

After more than 25 years in the pharma business, Andreas Katopodis founded the biotech company Anaveon together with Professor Onur Boyman. In 2019, the startup…

Jérémie Meyer06.12.2019

Features

In the news: From start-ups to the six Swiss exchange – A Swiss success story

Switzerland is consistently ranked the most innovative country in the world, especially when it comes to life sciences. Abi Millar, from Pharma Technology Focus, looks…

Jérémie Meyer03.10.2019

Jérémie Meyer

KPMG: COVID-19 feature- Build resilience

Anaveon raises CHF 35 million

Polyneuron raises CHF 22.5 million in Series A financing

Alentis raises 12.5 million Swiss francs

T3 Pharma raises over $12 million

Versameb raises 6.4 million Swiss francs

CHF 15M in Series A Financing, raised by ImmunOs

KPMG: Reshaping the future of pharma

“The first steps are slow and then suddenly things start rolling”

In the news: From start-ups to the six Swiss exchange – A Swiss success story

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us